Swiss pharmaceutical company Roche has announced that a new antibiotic, zosurabalpin, is progressing to phase 3 testing.

Researchers have created a pipeline for discovering unique combinations of molecules that increase the effectiveness of antibiotics against drug-resistant bacteria. The team, led by scientists at the ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...

A research team affiliated with UNIST has unveiled a novel extracorporeal blood purification technology that captures and ...

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

Roche is planning to move a new antibiotic into late-stage clinical trials after studies showed it had potential to tackle a ...

Critically ill patients with acute kidney injury could benefit from higher doses of the antibiotic colistin on the days they ...

In a second piece of good news in the development of new antimicrobials this week, GSK has said it will file its oral ...

A biotech company based out of Massachusetts found a tremendous amount of success mid-week after the company announced that ...

An experimental antibiotic zosurabalpin to fight deadly superbug has entered the final human trials. This development could ...

Special Report: Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives RECCE® 327 ...